Single dose abacavir pharmacokinetics and safety in neonates exposed to human immunodeficiency virus (HIV)
Date
2021-06
Journal Title
Journal ISSN
Volume Title
Publisher
Oxford University Press
Abstract
Abacavir is a potential option for prophylaxis and early treatment of human immunodeficiency virus (HIV), but no data are available in neonates. Ten neonates administered a single abacavir dose of 8 mg/kg before 15 days of life had substantially higher exposures than those reported in infants and children, with no reported adverse events.
Description
CITATION: Bekker, A. et al. 2020. Single Dose Abacavir Pharmacokinetics and Safety in Neonates Exposed to Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases, 72 (11): 2032–2034. doi:10.1093/cid/ciaa1026
The original publication is available at https://academic.oup.com/cid/
The original publication is available at https://academic.oup.com/cid/
Keywords
HIV infections -- Treatment, HIV (Viruses) -- Transmission, Antiretroviral agents, Pharmacokinetics, Neonatal intensive care, Perinatal pharmacology
Citation
Bekker, A. et al. 2020. Single Dose Abacavir Pharmacokinetics and Safety in Neonates Exposed to Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases, 72 (11): 2032–2034. doi:10.1093/cid/ciaa1026